MagPortal.com   Clustify - document clustering
 Home  |  Newsletter  |  My Articles  |  My Account  |  Help 

Location: Categories / Business / Industries / Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.
Old Articles: <Older 8121-8130 Newer>
The Motley Fool
December 9, 2011
David Williamson
1 Biotech Soars While Another Crashes Cell Therapeutics dilutes shareholders while SIGA squashes fears. mark for My Articles 35 similar articles
The Motley Fool
December 9, 2011
Paul Chi
3 Europe-Proof Stocks for Your Portfolio These health-care stocks are Europe-proof. mark for My Articles 309 similar articles
The Motley Fool
December 9, 2011
Harsh Chauhan
Medtronic Regains Its Footing Medtronic comes up with a strong quarter. mark for My Articles 294 similar articles
The Motley Fool
December 9, 2011
Marthe LaRosiliere
Intuitive Surgical: Plenty of Room to Grow The surgical-robot maker is nearly a 10-bagger since 2005, but its future remains bright. mark for My Articles 123 similar articles
The Motley Fool
December 8, 2011
Brian Orelli
A Soaring Biotech With Room to Run Affymax gets a leg up from an FDA advisory panel vote. mark for My Articles 101 similar articles
Chemistry World
December 8, 2011
Sarah Houlton
Academia Grows Its Role in Drug Discovery The number of pharma patents being filed by universities around the world is soaring compared with those coming from industry. mark for My Articles 547 similar articles
Chemistry World
December 8, 2011
Maria Burke
Government Launches UK Life Sciences Strategy Prime minister David Cameron has announced a package of measures designed to boost the UK's life sciences industry. mark for My Articles 209 similar articles
The Motley Fool
December 8, 2011
Luke Timmerman
Affymax Passes FDA Panel Scrutiny, Looks to Challenge Amgen Anemia Drug Many investors wrote off Affymax in June 2010, but was that premature? mark for My Articles 171 similar articles
The Motley Fool
December 8, 2011
Rebecca Lipman
Smart Money Picks: Biotech Stocks With Bullish Short Trends Do you agree with short-sellers' optimism for these names? mark for My Articles 152 similar articles
The Motley Fool
December 8, 2011
Dan Caplinger
Has Geron Become the Perfect Stock? Geron has a modest pipeline of cancer drugs, including imetelstat, which is currently in phase 2 clinical trials. mark for My Articles 181 similar articles
<Older 8121-8130 Newer>    Return to current articles.